ethyl 2-iminobutanoate | 75214-00-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 2-iminobutanoate
• 英文别名: Ethyl iminobutyrate
• CAS: 75214-00-5
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: UIKOVWUYANJUPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  exo-3-azatricyclo[4.2.1.0^2,5]non-7-en-4-one 、 ethyl 2-iminobutanoate 生成 4-ethyl-3,5-diazatricyclo[6.2.1.02,7]undeca-3,9-dien-6-one
  参考文献：
  名称：

  STAJER G.; SZABO E.; BERNATH G.; SOHAR P., MAGY. KEM. FOLYOIRAT, 92,(1986) N 5, 234-236

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl 2-azidobutanoate 在 正丁基锂 、 乙醇 作用下， 生成 ethyl 2-iminobutanoate
  参考文献：
  名称：

  Reaction of .alpha.-azido esters with lithium ethoxide: synthesis of dehydroamino esters and .alpha.-keto esters

  摘要：

  DOI：

  10.1021/jo01312a025

文献信息

• [EN] OXIME ESTER PHOTOINITIATORS<br/>[FR] PHOTOINITIATEUR ESTERS OXIMES
  申请人：CIBA HOLDING INC

  公开号：WO2009019173A1

  公开（公告）日：2009-02-12

  Compounds of the formula (I), wherein R1 is for example C2-C25alkenyl, C6-C20heteroarylalkyl, C3-C20alkoxycarbonylalkyl, C8-C20phenoxycarbonylalkyl, C6-C20heteroaryloxycarbonylalkyl, C6-C20heteroarylthioalkyl, C0-C20amino or C1-C20aminoalkyl or C1-C20alkyl substituted by formula (II); R2 is C1-C20alkyl; R4 and R5 independently of one another are hydrogen or C1-C20alkylcarbonyl; Ar is optionally substituted naphthyl, thienyl or furyl; exhibit an unexpectedly good performance in photopolymerization reactions.

  式(I)的化合物，其中R1例如是C2-C25烯基，C6-C20杂环烷基，C3-C20烷氧羰基烷基，C8-C20苯氧羰基烷基，C6-C20杂环氧羰基烷基，C6-C20杂环硫代烷基，C0-C20氨基或C1-C20氨基烷基或由式(II)取代的C1-C20烷基；R2是C1-C20烷基；R4和R5彼此独立地是氢或C1-C20烷基羰基；Ar是可选取代的萘基，噻吩基或呋喃基；在光聚合反应中表现出出乎意料的良好性能。
• Renal-selective biphenylalkyl 1H-substituted-1, 2, 4- triazole angiotensin I I antagonists for treatment of hypertension
  申请人：G.D. Searle & Co.,

  公开号：US20040220245A1

  公开（公告）日：2004-11-04

  Renal-selective compounds are described which, in one embodiment, are prodrugs preferentially converted in the kidney to compounds capable of blocking angiotensin II (AII) receptors. These prodrugs are conjugates formed from two components, namely, a first component provided by an AII antagonist compound and a second component which is capable of being cleaved from the first component when both components are chemically linked within the conjugate. The two components are chemically linked by a bond which is cleaved selectively in the kidney, for example, by an enzyme. The liberated AII antagonist compound is then available to block AII receptors within the kidney. Conjugates of particular interest are glutamyl derivatives of biphenylmethyl 1H-substituted-1,2,4-triazole compounds, of which N-acetylglutamic acid, 5-[[4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]]carbonylhydrazide, (shown below) is an example: 1

  本文描述了一种肾选择性化合物，其中，在一种实施例中，这些前药被优先转化为能够阻断血管紧张素II（AII）受体的化合物。这些前药是由两个组分形成的结合物，即由AII拮抗剂化合物提供的第一组分和当两个组分在结合物中化学连接时能够被从第一组分中裂解的第二组分。这两个组分通过一种在肾脏中有选择性的键进行化学连接，例如，通过一种酶。释放的AII拮抗剂化合物随后可用于阻断肾脏内的AII受体。特别感兴趣的结合物是双苯甲基1H-取代-1,2,4-三唑化合物的谷氨酰衍生物，其中N-乙酰谷氨酸，5-[[4'-(3,5-二丁基-1H-1,2,4-三唑-1-基)甲基][1,1'-联苯基]-2-基]甲酰肼（如下图所示）是一个例子：1
• Renal-selective biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin
  申请人：G. D. Searle & Co.

  公开号：US05217985A1

  公开（公告）日：1993-06-08

  Renal-selective compounds are described which, in one embodiment, are prodrugs preferentially converted in the kidney to compounds capable of blocking angiotensin II (AII) receptors. These prodrugs are conjugates formed from two components, namely, a first component provided by an AII antagonist compound and a second component which is capable of being cleaved from the first component when both components are chemically linked within the conjugate. The two components are chemically linked by a bond which is cleaved selectively in the kidney, for example, by an enzyme. The liberated AII antagonist compound is then available to block AII receptors within the kidney. Conjugates of particular interest are glutamyl derivatives of biphenylmethyl 1H-substituted-1,2,4-triazole compounds, of which N-acetylglutamic acid, 5-[[4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]]ca rbonylhydrazide, (shown below) is an example: ##STR1##

  本文描述了一种肾选择性化合物，其中，在一个实施例中，这些前药优先转化为能够阻断肾素-血管紧张素系统(AII)受体的化合物。这些前药是由两个组分形成的结合物，即由AII拮抗剂化合物提供的第一组分和当两个组分在结合物中化学连接时能够被裂解的第二组分。这两个组分通过一个键化学连接在一起，该键可以通过肾脏中的酶选择性地裂解。释放的AII拮抗剂化合物然后可用于阻断肾脏内的AII受体。特别感兴趣的结合物是双苯甲基1H-取代-1,2,4-三唑化合物的谷氨酰衍生物，其中N-乙酰谷氨酸、5-[[4'-[(3,5-二丁基-1H-1,2,4-三唑-1-基)甲基][1,1'-联苯]-2-基]]羰基肼，（如下所示）是一个例子：##STR1##
• Renal-selective biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonists for treatment of hypertension
  申请人：G.D. Searle & Co.

  公开号：US20040121989A1

  公开（公告）日：2004-06-24

  Renal-selective compounds are described which, in one embodiment, are prodrugs preferentially converted in the kidney to compounds capable of blocking angiotensin II (AII) receptors. These prodrugs are conjugates formed from two components, namely, a first component provided by an AII antagonist compound and a second component which is capable of being cleaved from the first component when both components are chemically linked within the conjugate. The two components are chemically linked by a bond which is cleaved selectively in the kidney, for example, by an enzyme. The liberated AII antagonist compound is then available to block AII receptors within the kidney. Conjugates of particular interest are glutamyl derivatives of biphenylmethyl 1H-substituted-1,2,4-triazole compounds, of which N-acetylglutamic acid, 5-[[4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]]carbonylhydrazide, (shown below) is an example: 1

  本文描述了肾脏选择性化合物，其中，在一种实施例中，这些前药被优先转化为能够阻断血管紧张素II（AII）受体的化合物。这些前药是由两个组分形成的共轭物，即由AII拮抗剂化合物提供的第一组分和当两个组分在共轭物中化学连接时能够被剪切的第二组分。这两个组分通过一种键化学连接，该键在肾脏中被选择性地剪切，例如，通过一种酶。释放的AII拮抗剂化合物随后可用于阻断肾脏内的AII受体。特别感兴趣的共轭物是双苯甲基1H-取代-1,2,4-三唑化合物的谷氨酰衍生物，其中N-乙酰谷氨酸，5-[[4′-[(3,5-二丁基-1H-1,2,4-三唑-1-基)甲基] [1,1′-联苯] -2-基] -羧酰肼（如下图所示）是一个例子：1
• Method for enantioselective carbene C—H insertion using an iron-containing protein catalyst
  申请人：California Institute of Technology

  公开号：US10934531B2

  公开（公告）日：2021-03-02

  Methods for catalyzing C—H insertion reactions using heme enzymes are described. The present disclosure provides a method for producing a C—H insertion product comprising providing an substrate having an sp3-hybridized C—H bond, a carbene precursor such as a diazo reagent, and a heme enzyme, and admixing the components in a reaction for a time sufficient to produce the C—H insertion product. Heme enzyme variants useful for carrying out in vivo and in vitro C—H insertion reactions, as well as expression vectors and host cells expressing the heme enzymes, are also described.

  描述了使用血红素酶催化 C-H 插入反应的方法。本公开提供了一种生产 C-H 插入产物的方法，包括提供具有 sp3 杂化 C-H 键的底物、碳烯前体（如重氮试剂）和血红素酶，并在反应中将各组分混合足够长的时间以生产 C-H 插入产物。此外，还介绍了用于进行体内和体外 C-H 插入反应的血红素酶变体，以及表达载体和表达血红素酶的宿主细胞。